CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: July 8, 2014
Result type: Reports
Project Number: SR0386-000
Product Line: Reimbursement Review

Generic Name: Lomitapide

Brand Name: Juxtapid

Manufacturer: Aegerion Pharmaceuticals (Canada) Ltd.

Therapeutic Area: Hypercholesterolemia, homozygous familial

Indications: Hypercholesterolemia, Homozygous Familial

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 17, 2015

Recommendation Type: Do not list